Categories: BioTechDataLearn
Creyon Bio applies purpose-built data sets to drive efficient creation of machine learning models to engineers oligonucleotide-based medicines (OBMs) for safe, precise gene-centric therapies with unprecedented speed and predictable efficacy and safety.
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.03.2022 | Seed | $40M | - |
Mentions in press and media 4
| Date | Title | Description |
| 09.03.2022 | Creyon Bio secures $40M | Creyon Bio has raised $40 million in seed and Series A financing co-led by DCVC Bio and Lux Capital. The company engineers RNA-based medicines and their components.
View round |
| 09.03.2022 |
Creyon Bio Gets $40M For Precision Medicine
| San Diego- and Research Triangle Park, NC-based Creyon Bio said Tuesday that it has raised $40M in a funding round. The funding was led by DCVC Bio and Lux Capital, along with Casdin Capital, Alexandria Venture Investments, and BioBrit. The... |
| 09.03.2022 | Creyon Bio receives $40M in Seed and Series A funding to future develop their platform and grow their team | - |
| 08.03.2022 | Creyon Bio Secures $40M in Seed and Series A Financing | Creyon Bio, a San Diego, CA and Research Triangle Park, NC-based drug development company, raised $40M in Seed and Series A funding.
The round was led by DCVC Bio and Lux Capital, with participation from Casdin Capital, Alexandria Venture I... |
Reviews 0
